ArriVent BioPharma AVBP
NASDAQ AVBP
$13.51 +0.02 (+0.11%)
At close: Nov 11, 2026 · 4:00 PM EST

ArriVent BioPharma (AVBP) Preferred Stock Liabilities (2022 - 2023)

Updated

ArriVent BioPharma's Preferred Stock Liabilities came in at $304.49 million for Q4 2023, unchanged from the prior quarter.

Analysis

ArriVent BioPharma (AVBP) Preferred Stock Liabilities (2022 - 2023) Analysis & Trends

Going back to Q1 2023, ArriVent BioPharma's Preferred Stock Liabilities data covers 4 quarters.

  • The five-year range for quarterly Preferred Stock Liabilities is $304.49 million (Q2 2023) to $304.51 million (Q1 2023).
  • Business Quant data shows AVBP's Preferred Stock Liabilities at $304.49 million (Q3 2023), $304.49 million (Q2 2023) and $304.51 million (Q1 2023) in the three quarters before Q4 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 ArriVent BioPharma 690.85 Mn -714.69 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 304.49 Mn
Sep 30, 2023 304.49 Mn
Jun 30, 2023 304.49 Mn
Mar 31, 2023 304.51 Mn
Dec 31, 2022 259.57 Mn
API Access

ArriVent BioPharma Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=AVBP&period=max&api_key=YOUR_API_KEY